Physician profile
Taryn Fortune
NPI 1659572089
$18,714.68
in general payments reported to CMS, 2019-2025
67 companies · $2,446 in 2025
The $2,446 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,659 · 2020: $1,460 · 2021: $2,353 · 2022: $3,193 · 2023: $3,552 · 2024: $3,051 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,048.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,504.65 | 2019-2025 | |
| Abbvie INC. | $2,475.81 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,638.33 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Pfizer INC. | $1,128.90 | 2021-2025 | |
| Biogen, INC. | $1,041.98 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Lilly USA, LLC | $1,011.70 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Ucb, INC. | $735.26 | 2019-2024 | Rystiggo |
| Lundbeck LLC | $511.72 | 2019-2025 | Vyepti, Rexulti |
| Amgen INC. | $464.75 | 2019-2025 | Uplizna |
| Sunovion Pharmaceuticals INC. | $449.67 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $415.43 | 2019-2025 | Ongentys, Rytary, Crexont |
| Alexion Pharmaceuticals, INC. | $398.96 | 2019-2024 | Soliris, Ultomiris |
| Genentech USA, INC. | $393.72 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $346.20 | 2019-2025 | |
| Banner Life Sciences, LLC | $325.12 | 2021-2024 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taryn Fortune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.